Elizabeth A. Dunlap/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
= Zolinza =
= Zolinza =
-
<StructureSection load='4LXZ' size='340' side='right' caption='Structure of Human HDAC2 in complex with SAHA (Vorinostat) PDB code 4LXZ' scene=''>
+
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
This is a default text for your page '''Elizabeth A. Dunlap/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
This is a default text for your page '''Elizabeth A. Dunlap/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
 +
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
== Function ==
== Function ==
-
Vorinostat (Zolinza) is an oral drug used as a cancer therapy to treat cutaneous T-cell lymphoma (CTCL) <ref name="four">Duvic, M., & Vu, J. (2007). Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics : Targets & Therapy, 1(4), 377–392. doi:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721288/</ref>. Vorinostat, previously known as suberoylanilide hydroxamic acid (SAHA), was the first HDAC inhibitor to be approved by the U.S. Food and Drug Administration on October 6, 2006 <ref name="five">National Cancer Institute. (2013). FDA Approval for Vorinostat. doi:https://www.cancer.gov/about-cancer/treatment/drugs/fda-vorinostat</ref>. Cancer cells tend to over-express histone deacetylase (HDAC). HDAC removes acetyl groups on histones which results in a structural change of chromatin. This change in chromatin structure leads to the repression of gene expression which would result in the proliferation of cancer cells. Vorinostat is an HDAC inhibitor that ultimately stops the uncontrolled growth of the cancer cells. Vorinostat does this by inhibiting the function of HDAC by binding to its zinc-binding site and blocking the removal of acetyl groups. Vorinostat is taken once a day by mouth. The most common side effects were fatigue and gastrointestinal symptoms<ref name="four"/>.
+
== Disease ==
-
== Structure ==
+
Lymphoma is a blood cancer that consists of lymphocytes (specific kinds of white blood cells) growing and multiplying without restriction. These cancerous cells are then dispatched to the lymph nodes, blood, bone marrow and spleen, among other organs. The accumulation of these cells forms a tumor. One type of lymphocyte that can develop into a cancerous cell is T-lymphocytes (T-cells). An extremely prevalent type of T-cell lymphoma is cutaneous T-cell lymphoma (CTCL) which involves T-cell lymphomas that inflict damage on the skin. CTCL is a non-Hodgkin type of lymphoma that can also have negative impacts on the lymph nodes, blood, spleen, and other organs. Patients often have dry skin accompanied with a rash and itching, as well as swollen lymph nodes. Patches, plaques, or tumors on the skin are characteristic of mycosis fungoides which is a mild type of CTCL. The majority of the time these symptoms are the only ones present, however, ten percent of patients that have later stages of the disease can develop severe complications. Sezary syndrome is a progressed form of mycosis fungoides that is identified by lymphoma cells appearing in the blood. This syndrome is systemic and chronic and has much more invasive symptoms such as red, itchy rashes covering over eighty percent of a patient’s body. Patients with this syndrome may also have patches and tumors on the skin, as well as alterations in hair, eyelids, nails, and enlargement of their lymph nodes. Zolinza is used to treat cutaneous manifestations that arise with CTCL, and this treatment is only recommended for patients that have undergone at least two systematic therapies with no improvement in their condition.
-
Zolinza contains vorinostat which is a histone deacetylase (HDAC) inhibitor. It’s IUPAC name is N'-hydroxy-N-phenyloctanediamide <ref name="seven">Grant, S., Easley, C., & Kirkpatrick, P. (2007) Fresh from the Pipline, Vorinostat. Nature Publishing Group. doi:http://www.nature.com/nrd/journal/v6/n1/full/nrd2227.html</ref>. Vorinostat has a molecular formula of C14H20N2O3 and a molecular weight of 263.32 g/mol <ref name="nine">Bubna, A. K. (2015). Vorinostat—An Overview. Indian Journal of Dermatology, 60(4), 419.
+
== Relevance ==
-
http://doi.org/10.4103/0019-5154.160511</ref>. It has a melting point ranging from 159 to 160.5 degrees Celsius. This HDAC inhibitor is completely soluble in dimethylsulfide, somewhat soluble in water, ethanol, isopropanol, and acetone, and insoluble in methylene chloride <ref name="three">Merck & Co Inc. (2015). Highlights of Prescribing Information: Zolinza. doi:https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf</ref>. It’s pH value in water solution is 6.6 with a pKa value of 9.2. <ref name="nine">
+
 
 +
== Structural highlights ==
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
-
== Disease ==
+
</StructureSection>
-
 
+
-
Zolinza is used to treat cutaneous manifestations that arise with CTCL, and this treatment is only recommended for patients that have undergone at least two systematic therapies with no improvement in their condition <ref name="three"/>.
+
-
 
+
-
== Mechanism ==
+
-
 
+
-
Zolinza is a potent nanomolar inhibitor of histone deacetylase (HDAC) activity, and this inhibition of activity can alternate the transcription of numerous genes via acetylation and transcription factors. It induces growth arrest, differentiation, or apoptosis in a variety of transformed cells. Zolinza induces up to a nine-fold increase in p21WAF1, a cell kinase inhibitor, mRNA and protein in T24 bladder carcinoma cells. This is caused by an increase in the rate of gene transcription associated with acetylation of the histones H3 and H4, associated with the p21WAF1 promoter. Zolinza also promotes the acetylation of numerous transcription factors like the androgen receptor, E2F-1, YY1, Smad7, EKLF, etc. In addition to histones and transcription factors, it also shows the acetylation of lysine residues of proteins, such as a-tubulin and protein Hsp90. Inhibition of HDAC6 activity leads to acetylation and the disruption of Hsp90, which leads to the decreased of progrowth activity and survival of proteins such as Bcr-Abl, mutant FLT-3, c-Raf and AKT in human leukaemia cells. Zolina has the ability to influence the ability of tumor cells to undergo mitosis by disrupting the cell cycle and induce apoptosis of tumor cells by targeting cell cycle checkpoints. In vitro studies show that HDAC inhibitors create spindles that interfere with chromosome attachment, resulting in mitotic accumulation without affecting microtubules <ref name="nine"/>.
+
-
 
+
== References ==
== References ==
<references/>
<references/>

Revision as of 00:15, 30 March 2017

Zolinza

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  2. ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644

Proteopedia Page Contributors and Editors (what is this?)

Elizabeth A. Dunlap

Retrieved from "http://52.214.119.220/wiki/index.php/Elizabeth_A._Dunlap/Sandbox_1"
Personal tools